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Background: Few studies have examined the role of cardiovascular drugs on acute ischaemic stroke
prognosis.
Aims: To evaluate the relationship between a favourable outcome in patients with acute ischaemic stroke and
speciﬁc demographic, clinical and laboratory variables and cardiovascular drug pretreatment.
Methods: The 1096 patients enrolled in the GIFA study (who had a main discharge diagnosis of ischaemic
stroke) represent the ﬁnal patient sample used in this analysis. Drugs considered in the analysis included
angiotensin converting enzyme (ACE)-inhibitors, angiotensin II receptor blockers, statins, calcium channel
blockers, anti-platelet drugs, vitamin K antagonists and heparins. The outcomes analyzed included in-
hospital mortality, cognitive function evaluated by the Hodkinson Abbreviated Mental Test (HAMT), and
functional status evaluated by activities of daily living (ADL). The deﬁnition of a good outcome was no in-
hospital mortality, a HAMT score of≥6 and no ADL impairment.
Results: Patients with no in-hospital mortality, a HAMT score of N6 and no ADL impairment were more likely
to be younger at baseline and have a lower blood glucose level and a systolic blood pressure (SBP) between
120 and180 mmHg, a higher plasma total cholesterol level, a lower white blood cell count, and a lower
Charlson Index (CI) score, a higher rate of pretreatment with ACE-inhibitors, calcium channel blockers and a
lower rate of pretreatment with heparin.
Conclusions: Predictorsof goodoutcome, in termsof in-hospitalmortality andcognitive and functionalperformance
at discharge, included higher SBP at admission between 120 and180mmHg, a SBP plasma total cholesterol levels, a
lower CI score, and pretreatment with ACE-inhibitors, calcium channel blockers and anti-platelets.
© 2010 Published by Elsevier Ireland Ltd.1. Introduction
Recognition of factors predictive of outcome in ischaemic stroke
management seems essential for optimizing therapeutic proce-
dures, especially those that are costly and time-consuming. Previous
data have underlined the possible prognostic role of demographic
and clinical variables at admission [1,2]. Data from a study by Selim
et al. [3], comparing stroke severity in patients who were, or were
not, taking ACE-inhibitors (ACE-I) before stroke onset, suggested
that ACE-I may reduce the clinical severity of stroke, as measured by
the National Institutes of Health Stroke Scale (NIHSS) scores.onﬂicts of interest to disclose.
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et al, Effects of clinical and la
rt review from the GIFA stuFurthermore, Sanossian et al. [4] showed that pre-stroke use of
anti-platelet drugs (APLs) may be associated with a reduced
severity of incident ischaemic strokes and an increased likelihood
of a good discharge outcome, regardless of cerebrovascular event
history, in those with no prior history of stroke or transient
ischaemic attack.
All of these studies evaluated the effects of clinical/laboratory
variables and cardiovascular drugs on NIHSS scores, but, to our
knowledge, no study has evaluated their possible effects on in-
hospital mortality or other outcomes, such as functional status and
cognitive impairment.
The aim of this study was to evaluate the relationship between a
favourable outcome in patients with acute ischaemic stroke and
speciﬁc demographic, clinical and laboratory variables and pretreat-
ment with cardiovascular drugs, such as angiotensin converting
enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs),
calcium channel blockers (CCBs), anti-platelet agents (APLs), vitamin
K antagonists (VKAs) and heparins [low molecular weight heparins
(LMWHs) and unfractioned heparin (UFH)].boratory variables and of pretreatment with cardiovascular drugs in
dy, Int J Cardiol (2010), doi:10.1016/j.ijcard.2010.06.005
Table 2
General and clinical characteristics in patients with acute ischaemic stroke.
Number of patients with acute ischaemic stroke 1096
Age, years 73.452±6.2
Female, n (%) 580 (52.91)
Male, n (%) 515 (46.98)
Hypertension, n (%) 391 (35.67)
Diabetes mellitus, n (%) 198 (18.06)
Temperature at admission, °C 36.9±0.72
Length of hospital stay, days 15.4±6.4
Blood glucose, mg/dL 132.89±65.17
SBP, mmHg 159.9±28.73
SBP N140 mmHg, n (%) 420 (38.3)
DBP, mmHg 87.16±13.2
DBP N90 mmHg, n (%) 177 (16.15)
WBC count at admission, cells/mm³ 8996±3887
ESR, mm/h 28.4±15.0
Plasma total cholesterol, mg/dL 213.6±4.0
Plasma triglyceride, mg/dL 155.2±76.1
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2.1. Patients and setting
The protocol of the GIFA (Italian Group of Pharmacoepidemiology in the Elderly)
study has been published elsewhere [5]. Brieﬂy, GIFA is a multicenter periodical survey
of hospitalized elderly patients. All patients admitted to the 81 clinical centers,
homogeneously distributed throughout Italy, were enrolled and followed-up until
discharge. The study periods were the following: May 1 to June 30 and September 1 to
December 31, 1988; May 15 to June 15, 1991; and May 1 to June 30 and September 1 to
October 31 in 1993, 1995, 1997, and 1998. For each participant, a questionnaire was
completed at admission and updated daily by a study physician who had received
speciﬁc training. Data recorded included patient demographic characteristics, medica-
tions used before admission, during the pre-hospital period and those prescribed
during hospital stay and at discharge, and admission and discharge diagnoses.
Our study population was limited to 17,377 patients for whom laboratory values
were available; patients with a ﬁnal diagnosis of acute ischaemic stroke comprised the
ﬁnal sample.
2.2. Disease prevalence and comorbidity
All diseases diagnosed by the physicians were classiﬁed according to the
International Classiﬁcation of Disease, 9th revision (ICD-9), with cases of ischaemic
stroke identiﬁed on the basis of the ICD-9 code (434 to 434.9, 436, and 433.01,
respectively). To estimate the global burden of disease, an index of comorbidity was
calculated using the Charlson Index (CI) score, modiﬁed by Deyo et al. [6]. Patients were
classiﬁed into three comorbidity groups based on a CI score of 0, 1–2 or N2.
2.3. Interventions
All drugs prescribed prior to hospital admission were obtained from hospital charts
and codiﬁed according to the anatomical therapeutic chemical classiﬁcation. Drugs
considered in the analysis included ACE-I, ARBs, CCBs, APLs, VKAs and heparin.
2.4. Outcome measures
The primary outcomes of this study were in-hospital mortality, cognitive
impairment at discharge and functional status at discharge.
Cognitive function was assessed using the Hodkinson Abbreviated Mental Test
(HAMT), a 10-item screening test for dementia [7]. The presence of cognitive
impairment was identiﬁed by the presence of≥4 errors on the test administered at
discharge, with a score of b6 suggesting cognitive impairment.
Functional status was evaluated using six basic activities of daily living (ADL),
including transferring from bed to chair, walking in a small room, eating, bathing, using
the toilet, and personal hygiene procedures. Patients were considered having severe
disability if they needed intensive assistance in at least one ADL, and were considered
having mild-to-moderate disability if they needed only supervision or limited
assistance in at least one ADL at the time of hospital discharge. Patients were stratiﬁed
by their level of ADL impairment into two groups based on disability grade: 0 (no ADL
impairment) and 1–6 (with ADL impairment).
2.5. Statistical analysis
We assessed the association between outcome indicators of acute ischaemic stroke,
some analysis variables (Table 1) and pretreatment with cardiovascular drugs, such asTable 1
Analysis variables.
Parameter Variable
In-hospital mortality Yes vs. No
HAMT score ≥6 vs. b6
ADL-impairment 0 vs. 1–6
Demographic variables
Age (Years)
Gender M vs. F
Laboratory variables
Blood glucose levels N200 mg/dL vs. b200 mg/dL
Plasma cholesterol levels Serum, mg/dl
White blood cell count N10,000 cells/mm3 vs. b10,000 cells/mm3
Systolic blood pressure N140 mmHg vs. b140 mmHg
Diastolic blood pressure N90 mmHg vs. b90 mmHg
Baseline clinical variables
Charlson Index score N2 vs. b2
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outcome categories against each chosen potential predictive variable (yes versus no).
The proportions of patients with or without in-hospital mortality, with or without
cognitive impairment and with or without ADL impairment were compared using
contingency tables and the χ² test. A forward logistic regression analysis was
performed with indexes of favourable outcome at discharge, such as no in-hospital
mortality, a HAMT score of≥6 and no ADL impairment, as the dependent variables
(analyzed separately for each outcome indicator). Variables in this analysis were
selected from univariate analysis (Student's t-test, contingency tables, and Mann–
Whitney U test) when they reached a signiﬁcance level of≤0.05. For all statistical
analyses, results were considered signiﬁcant when pb0.05. All statistical analyses were
performed with SPSS software.
3. Results
The demographic, clinical and laboratory variables of the 1096 patients with acute
ischaemic stroke who were recruited are shown in Table 2. Data for HAMT score and
ADL impairment were available for only 514 (46.89%) and 843 (76.91%) patients,
respectively.
Information about duration of pre-hospital treatment was available in 987 subjects
(90.05%); mean duration (±dS) was 2.5±1.2 years for ACE-I, 3.7±years for CCBs, 2.8±
0.9 years for APLs and 9.2±3.5 months for heparins.
Lack of some coprimary endpoints in a proportion of patients is consistent with the
multicenter nature of our study due to registration problems in some peripheral centers.
3.1. Univariate analyses
Patients with no in-hospital mortality compared with patients with in-hospital
mortality had: a lower age; a lower blood glucose level at admission; a lower
percentage of patients with blood glucose levels N200 mg/dL; a higher systolic blood
pressure (SBP) at admission; a higher percentage of patients with SBP≥120
and≤180 mmHg; a higher plasma level of total cholesterol; a lower WBC count; a
lower CI score; a higher percentage of patients with a CI score b2; a higher percentageCharlson Index score (mean/median) 2.95/3
Charlson Index score
1–2, n (%) 333 (30.38)
N2, n (%) 763 (69.61)
In-hospital mortality, n (%) 247 (22.53)
HAMT score at dischargea, n (%) 514 (46.89)
HAMT score b6, n (%) 237 (46.10)
HAMT score N6, n (%) 277 (53.89)
ADL at dischargea, n (%) 843 (76.91)
No ADL impairment, n (%) 293 (34.75)
1–6 ADL impairment, n (%) 550 (65.24)
Pretreatment at admission
Statin, n (%) 16 (1.45)
ACE-inhibitors, n (%) 431 (39.32)
Angiotensin II receptor blockers, n (%) 4 (0.36)
Anti-platelet drugs, n (%) 341 (31.11)
Anti-vitamin K drugs, n (%) 55 (5.01)
Calcium channel blockers, n (%) 565 (51.55)
Heparin, n (%) 307 (28.01)
ADL=activities of daily living; DBP=diastolic blood pressure; ESR=erythrocyte
sedimentation rate; HAMT=Hodkinson Abbreviated Mental Test; SBP=systolic blood
pressure; WBC=white blood cell.
Data given as mean±standard deviation unless otherwise stated.
a Patients for whom the measurement was available.
boratory variables and of pretreatment with cardiovascular drugs in
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Table 4
Logistic regression with no in-hospital mortality as the dependent variable.
Regression
coefﬁcient
Odds
ratio
95% CI p-value
Age, years −0.11 0.91 0.92–0.99 0.024
SBP at admission 1.61 5.55 1.42–17.8 0.012
SBP≥120 and≤180 mmHg 1.48 2.78 1.97–3.35 b0.001
SBP N180 mmHg −0.39 0.79 0.60–0.87 b0.005
SBP b120 mmHg −0.38 0.77 0.61–0.85 b0.005
White blood cell count −025 0.58 0.35–0.73 0.0110
Plasma cholesterol level 0.89 2.12 1.33–4.3 0.020
Blood glucose level N200 mg/dL −0.32 0.75 0.65–0.80 b0.0001
Charlson Index score b2 1.02 4.12 1.42–17.8 0.012
Charlson Index score N2 −0.27 0.80 0.65–0.91 0.0231
ACE-inhibitors 1.61 3.42 1.88–8.1 0.012
Calcium channel blockers 1.55 5.12 1.92–12.8 0.014
Anti-platelet drugs 1.21 4.94 2.1–11.2 0.023
Heparin −0.29 0.77 0.65–0.81 ≤0.0001
ACE-I=ACE-inhibitors; SBP=systolic blood pressure.
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ACE-I, CCBs, APLs or VKAs; and a lower percentage of patients pretreated at admission
with heparin (Table 3).
Patients with a HAMT score of≥6 at discharge compared with patients with a
HAMT score of b6 at discharge had: a lower age; a lower blood glucose level at
admission; a higher percentage of patients with blood glucose levels N200 mg/dL; a
higher percentage of patients with SBP≥120 and≤180 mmHg; a higher plasma total
cholesterol level, a higher plasma triglyceride level; a lower WBC count; a higher
percentage of patients with a CI score b2; a higher percentage of patients with no ADL
impairment; and a higher percentage of patients pretreated at admission with ACE-I
(Table 3).
Patients with no ADL impairment at discharge compared with patients with 1–6 ADL
impairment at discharge had: a lower age; a lower blood glucose level at admission; a
lower percentage of patients with blood glucose levels N200 mg/dL; a higher SBP at
admission; a higher percentage of patientswith SBP≥120 and≤180 mmHg; a lowerWBC
count; a lower CI score; a higher percentage of patients pretreatedwith ACE-I; and a lower
percentage of patients pretreated with heparin (Table 3).
3.2. Logistic regression analyses
No in-hospital mortality was positively associated with SBP at admission, an
SBP≥120 and≤180 mmHg at admission, plasma cholesterol levels, a CI score b2 and
with ACE-I, CCB and APL pretreatment (Table 4).
A HAMT score of N6 at discharge was found to be positively associated with SBP at
admission, an SBP≥120 and≤180 mmHg at admission, plasma cholesterol levels, a CI
score b2 and with ACE-I and APL pretreatment (Table 5).
Furthermore, no ADL impairment at discharge was positively associated with an
SBP≥120 and≤180 mmHg, a CI score b2 and with ACE-I and APL pretreatment
(Table 6).
4. Discussion
Our study suggests that higher baseline SBP and plasma total
cholesterol level, a lower CI score and pretreatment with ACE-I, CCBs
and APLs are predictors of a better short-term outcome, in terms of in-Table 3
Variables related to outcome (in-hospital mortality, disability and cognitive function) at dis
In-hospital
mortality
No in-hospital
mortaliy
p-value HA
n (%) 247 (22.53) 849 (77.46) b0.0001 27
Age, years 80.49±7.35 75.65±6.46 b0.005 79
Males, n (%) 113 (45.74) 391 (46.05%) 0.37 16
Blood glucose at admission, mg/dL 158.29±83.38 126.14±57.62 b0.01 12
Blood glucose N200 mg/dL, n (%) 35 (14.17) 63 (7.42) b0.005 38
SBP at admission, mmHg 148.80±32.69 160.16±27.87 b0.0001 15
DBP at admission, mmHg 86.63±15 87.26±12.96 0.78 84
SBP≥120 and≤180 mmHg 72 (29.14) 513 (60.42) b0.0001 65
SBPb120 mmHg 94 (29.95) 171 (20.14) 0.029 11
SBP N180 mmHg 101 (40.89) 165 (19.43) b0.0001 10
Plasma cholesterol, mg/dL 191.74±51.75 200.53±50.92 0.039 20
Plasma triglyceride, mg/dL 148.48±91.01 145.74±87.36 0.37 15
Diabetes mellitus, n (%) 39 (15.78) 147 (17..31) 0.38 53
WBC count cells/mm3 11001.27±4408.8 8467±3557.8 b0.0001 6 2
WBC N10,000 cells/mm3, n (%) 41 (16.59) 90 (10.61) b0.05 74
Charlson Index score (mean) 3.9 3.1 0.035 3.7
Charlson Index score b2, n (%) 166 (67.21) 728 (85.75) b0.05 19
Charlson Index score N2, n (%) 81 (32.79 ) 121 (14.25) b0.0001 86
AMTD N6 (%) 69 (28.39 ) 236 (31.42) 0.55 –
AMTD b6 (%) 46 (23.95) 231 (30.75) 0.021 –
No ADL impairment, n (%) 76 (30.71) 414 ( 55.1) b0.0001 91
1–6 ADL impairment, n (%) 36 (18.75) 337 (44.87) b0.0001 18
Pre-hospital drug use
Statin, n (%) – – – –
ACE-I, n (%) 18 (6.5) 125 (14.7) b0.0001 63
ARBs, n (%) – – – –
CCBs, n (%) 58 (12.36 ) 411 (87.63 ) b0.0001 71
APLs, n (%) 16 (6.47) 204 (24.02) b0.0001 43
VKAs, n (%) 1 (0.41) 42 (4.94) b0.0001 14
Heparin, n (%) 89 (36.62) 218 (25.67) b0.05 16
ACE-I=ACE-inhibitors; ADL=activities of daily living; AMTD=adjusted mean treatme
CCBs=calcium channel blockers; DBP=diastolic blood pressure; ESR=erythrocyte sed
pressure; WBC=white blood cell; VKA=vitamin K antagonist.
p-values of signiﬁcance (pb0.05) are in bold.
Data given as mean±standard deviation unless otherwise stated.
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patients with acute ischaemic stroke. Patients with baseline SBP≥120
and ≤180 mmHg and lower total cholesterol level, a higher CI score,
and those who did not receive cardiovascular drugs and were
pretreated with heparin had a worse outcome.
Stroke case fatality has been used as a proxy measure of hospital
performance and quality of care to compare across hospitals, provinces,
and countries [8]. In addition, 7 day case fatality was recently im-
plemented as an indicator of early stroke mortality, because the most
important clinical decisions are made in the ﬁrst week after hospital
admission [9].charge in patients with acute ischaemic stroke at univariate analysis.
MT N6 HAMT b6 p-value No ADL-
impairment
1–6 ADL-
impairment
p-value
7 (53.89) 237 (46.10) b0.001 293 (34.75) 550 (65.24) b0.001
.23±8.66 81.33±7.23 0.041 72.85±.38 78.49±9.25 b0.005
3 (58.84) 99 (41.77) b0.001 164 (55.97) 297 (54) 0.038
4.05±61.81 143.16±84.4 b0.001 123.74±60.18 137.28±73.31 0.021
(13.71) 24 (10.12) b0.001 34 (11.60) 111 (20.18) b0.005
1.18±26.08 153.04±27.52 0.06 154.28±27.23 149.32±28.13 0.045
.84±14.04 85.85±12.67 0.07 84.18±13.53 85.89±13.27 0.78
(23.46) 41 (17.29 ) 0.021 65 (22.18 ) 93 (16.90) b0.005
1 ( 40.07 ) 135 (56.96 ) 0.038 157 (53.58) 236 (42.90) b0.023
1 (36.46) 61 (25.73) 0.021 71 (24.23 ) 221(40.18) b0.005
2.32±20.92 194.54±31.75 0.038 199.74±51.75 201.53±50.92 0.43
6.8.±57.01 145.74±87.36 0.023 147.83±91.01 144.54±67.36 0.07
(19.13 ) 44 (18.56) 0.61 55 (18.77) 102 (18.54 ) 0.45
97±4251 9495±3029 0.011 8990±2251 9840±3251 0.04
(26.71) 74 (31.22) 0.021 44 (15.01) 143 (26) b0.005
6 3.83 0.87 3.9 / 4 4/4.2 b0.005
2 (69.31) 121 (51.05) 0.021 181 (61.77) 343(62.36) 0.71
(31.04 ) 47 (19.83 ) b0.005 107 (36.51) 206 (37.45) 0.56
– – 172 (58.70) 323 (58.72) 0.70
– – 175 (59.72) 226 (41.09) 0.56
(32.85) 48 (20.25) b0.005 – – –
6 (67.14) 193 (81.43) b0.005 – – –
– – – – –
(22.74) 39 (16.45) 0.023 81 (27.64) 101 (18.36) b0.005
– – – – –
(25.63) 57 (24.05 ) 0.71 71 (24.23) 129 (23.45 ) 0.31
(15.51) 35 (14.76) 0.57 41 (13.93) 82 (14.90) 0.89
(5.04) 12 (5.06 ) 0.44 9 (3.07) 15 (2.7) 0.91
(5.77) 14 (5.90) 0.37 11 (3.75) 31 (5.6) 0.041
nt difference; APLs=antiplatelets drugs; ARBs=Angiotensin II receptor blockers;
imentation rate; HAMT=Hodkinson Abbreviated Mental Test; SBP=systolic blood
boratory variables and of pretreatment with cardiovascular drugs in
dy, Int J Cardiol (2010), doi:10.1016/j.ijcard.2010.06.005
Table 5
Logistic regression with HAMT score N6 at discharge as the dependent variable.
Regression
coefﬁcient
Odds
ratio
95% CI p-value
Age −0.19 0.84 0.72–0.95 0.035
Blood glucose level N200 mg/dL −0.35 0.81 0.56–0.87 b0.05
SBP≥120 and≤180 mmHg 1.44 2.35 1.68–5.2 0.012
SBP N180 mmHg −0.30 0.82 0.65–0.93 0.031
SBPb120 mmHg −0.29 0.70 0.62–0.89 0.029
Plasma cholesterol level 0.69 1.78 1.41–4.6 0.022
Blood glucose level N200 mg/dL 1.23 4.64 1.55–11.8 0.020
White blood cell count −0.21 0.79 0.61–0.93 0.012
Charlson Index score b2 1.31 3.11 1.88–5.1 0.010
Charlson Index score N2 −0.32 0.86 0.69–0.92 0.020
ACE-inhibitors 1.44 5.55 2.34–12.9 b0.0001
Anti-platelet drugs 1.39 4.79 2.11–8.81 b0.05
Heparin −0.37 0.79 0.41–0.91 0.018
ACE-I=ACE-inhibitors; SBP=systolic blood pressure.
4 A. Tuttolomondo et al. / International Journal of Cardiology xxx (2010) xxx–xxxA transient increase in arterial BP frequently occurs in patients
with acute stroke [10–12]. This could be a physiological response to
maintain or enhance perfusion of a reversibly damaged cerebrum
when normal autoregulatory mechanisms are impaired.
In a recent overview, Bath [13] reported that some studies failed
to establish a relationship between admission BP and outcome,
although others suggested that low or high SBP may be associated
with poor outcome [14]. In our study, patients with an SBP≥120
and≤180 mmHg at admission and a higher mean SBP at admission
had better outcomes (no in-hospital mortality, a HAMT score of N6
and no ADL impairment at discharge). This could represent an
interesting observation that may alter the management of acute
ischaemic stroke.
These ﬁndings conﬁrm that the relationship of our outcome
indicators to the SBP-on admission may follow a U-shaped curve as
reported by other studies [15]. Nevertheless our ﬁndings could
indicate a larger nadir or U-point of the curve that occurred in the
range of 120–180 mmHg for SBP values, respectively. Indeed our
ﬁndings showed that only SBP ≥120 and≤180 mmHg is associated
with no mortality, no cognitive impairment and no ADL impaired
whereas both SBP b120 and N180 mmHg are associated with
intrahospital mortality and cognitive impairment.
Although the association between serum cholesterol levels and
cerebrovascular disorders has been extensively studied, the relation-
ship between cholesterol levels and outcome following ischaemic
stroke has been investigated in only a few studies. Vauthey et al.
[16] showed that, compared with patients with normal cholesterol
levels, patients with high cholesterol levels had a 2.2-fold lower risk of
death and a 2.1-fold lower risk of a poor functional outcome at
1 month. More recently, a population study [17] reported that serumTable 6
Logistic regression with no ADL impairment at discharge as the dependent variable.
Regression
coefﬁcient
Odds
ratio
95% CI p-value
Age −0.16 0.88 0.77–0.96 0.021
Blood glucose level N200 mg/dL −0.37 0.83 0.37–0.78 b0.05
SBP≥120 and≤180 mmHg 1.43 2.12 1.54–2.79 ≤0.0001
SBP N180 mmHg −0.37 0.71 0.68–0.86 0.018
SBPb120 mmHg −0.34 0.77 0.66–0.867 0.019
White blood cell count −0.31 0.75 0.61–0.86 0.015
White blood cell count N10,000
cells/mm3
−0.24 0.77 0.55–0.86 0.022
Charlson Index N2 −0.31 0.82 0.61–0.88 b0.05
Charlson Index b2 1.34 2.51 1.78–9.6 b0.0001
ACE-inhibitors 1.41 2.25 1.65–6.99 b0.05
Anti-platelet drugs 1.35 2.95 1.98–9.87 b0.0001
Heparin −0.25 0.80 0.64–0.91 0.013
ACE-I=ACE-inhibitors; SBP=systolic blood pressure.
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severity.
Our ﬁnding concerning the association between higher plasma
total cholesterol levels and lower rates of in-hospital mortality,
cognitive impairment and disability at discharge, is an interesting
observation that, to our knowledge, has not been reported before. It is
conceivable that low cholesterol levels may reﬂect a state of general
malnutrition [18] and that inﬂammatory markers may impact on
plasma cholesterol levels, with acute-phase markers being indepen-
dently associated with low levels of total and high density
lipoprotein-cholesterol [19]. So, our ﬁnding of a better outcome in
patients with higher plasma cholesterol levels could be related to a
lower rate of acute immuno-inﬂammatory activation after acute
ischaemic stroke.
We reported that WBC count is signiﬁcantly associated with in-
hospital mortality, cognitive impairment and disability at discharge,
conﬁrming the data of Kazmierski et al. [20] who reported that an
increased WBC count within the ﬁrst 12 h of onset of an ischaemic
stroke is a prognostic factor for in-hospital mortality, probably
owing to the fact that WBC count may reﬂect the extent of ischaemic
damage and the magnitude of the inﬂammatory response to the
ischaemic event.
Moreover, our study shows (using univariate and logistic re-
gression analyses) that patients receiving ACE-I, CCBs and APLs before
the onset of strokewere less likely to experience in-hospital mortality.
In fact, ACE-I pretreatment was associated with each of the good
outcome indicators (no in-hospital mortality, a HAMT score of N6 and
no ADL impairment). The mechanisms by which these drugs provide
clinical beneﬁt in patients with acute ischaemic stroke remain
speculative, although are thought likely to be multifactorial, such as
anti-inﬂammatory [21], neuroprotective [22], pro-ﬁbrinolytic [23]
and improving cerebral basal ﬂow (CBF) [24] properties.
Saposnik et al. showed that not using antithrombotics during
hospital admission was one of the most consistent predictors of case
fatality at 7 days, 30 days, and 1 year after stroke [25]. APLs and ACE-I
are commonly used for stroke prevention.
Although some trials have assessed the role of CCBs in the acute
stroke setting [26], few have addressed their safety and efﬁcacy in
secondary prevention. It is widely accepted that N-methyl-D-aspartic
acid-mediated calcium inﬂux contributes to cell death following
cerebrovascular ischaemia. Despite the advancing knowledge of
calcium signalling in neurite outgrowth and recovery, little is
known about the clinical effect of calcium antagonism during the
recovery period following stroke. Recently, Dowlatshahi et al. [27]
showed in a cohort from the registry of the Canadian Stroke Network
that patients who were admitted on CCBs had improved outcomes at
6 months if they were also discharged on CCBs, compared with those
who had their CCBs discontinued. To our knowledge, no study has
previously evaluated the role of CCB treatment in acute stroke
prognosis, so our ﬁndings appear novel in this regard.
Our ﬁndings concerning heparin pretreatment are especially
interesting. A considerable number of our patients had been pre-
treated with heparin at the time of admission and we found an
association between reported heparin use and increased in-hospital
mortality. The exact role of heparins in the hyper-acute stage of
ischaemic stroke is still unclear. A recent Cochrane analysis [32]
showed no beneﬁts, but there are insufﬁcient data to ascertain their
effects on other important outcomes, including death and intracranial
haemorrhage. Nevertheless, our ﬁndings may suggest a disadvantage,
perhaps linked to a higher rate of haemorrhagic transformation,
although we currently do not have data to support this theory.
Some possible limitations of our study include the fact that we
used two uncommonly used functional measures of stroke outcome
(HAMT and ADL impairment). These were chosen because measures
of acute neurological deﬁcit, such as the NIHSS or Scandinavian Stroke
Scale, or measures of disability, such as the Rankin or the Barthelboratory variables and of pretreatment with cardiovascular drugs in
dy, Int J Cardiol (2010), doi:10.1016/j.ijcard.2010.06.005
5A. Tuttolomondo et al. / International Journal of Cardiology xxx (2010) xxx–xxxIndex, were not evaluated in the GIFA study. Furthermore, given the
short time frame of evaluation (discharge), the HAMT score may not
accurately reﬂect the long-term cognitive impact of stroke, after
accounting for stroke recovery in the chronic stage. Similarly, the ADL
score at discharge may not accurately reﬂect stroke recovery. So, an
extended follow-up is probably necessary to assess long-term
outcomes. Nevertheless, HAMT is an effective screening tool for
cognitive impairment in older, community-dwelling, hospitalized or
institutionalized adults, as well as acute cerebrovascular patients [28]
whereas ADL evaluation [29] has been used to determine the
inﬂuence of initially lowered orientation on rehabilitation outcomes
in stroke patients.
Other possible limitations of our study include its retrospective
nature, the paucity of HAMT data and the almost complete absence of
patients treated with statins, owing to the fact that the data analyzed
were obtained from 1993 to 1998, a period of less wide-spread statin
use. Nevertheless, in our opinion, this latter limitation represents a
possible advantage, since our study evaluated the relationship of
some cardiovascular drugs, such as ACE-I, CCBs and APLs, in patients
not treated with statins, and hence shows the real effects of these
drugs on stroke prognosis independent of statin treatment which, in
the last few years, has shown positive effects on stroke outcome
[30,31].
A further limitation is that in GIFA Database there were no
available NIHSS and TOAST subtype data owing to the fact that GIFA
was not a stroke patient database but is a multicenter periodical
survey of hospitalized elderly patients with several admissions from
whom we choose to analyze stroke patients extracted on the basis of
ICD-9 code.
In conclusion, we found that the use of ACE-I, CCBs and APLs before
an acute ischaemic stroke may improve patient outcome, whereas
heparin use may worsen outcome. However, deﬁnitive recommenda-
tions for the use of these drugs in stroke patients must await further
experimental and clinical data.
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